New combo therapy aims to shrink tumors in hard-to-treat cancers
NCT ID NCT03915678
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with these cancers will receive the combination treatment. The main goal is to see how many patients have their disease controlled (shrink or stay stable) within 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Poitiers
Poitiers, 86000, France
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Chu Brest
Brest, 29200, France
-
Hôpital La Timone
Marseille, 13005, France
-
IUCT Oncopôle
Toulouse, 31052, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie
Paris, 75005, France
-
Institut Paoli Calmettes
Marseille, 13273, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a Bag-Like device pull bladder tumors out whole?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a vaccine help fight Hard-to-Treat cancers?